The Company expects full year 2025 gross margin to be approximately 64.5%. Should global tariff rates remain at current levels, the Company estimates a potential gross margin headwind of approximately $5.0 million, representing a reduction of approximately 150-basis points from our baseline guidance of 64.5%. The majority of this impact is anticipated in the second half of 2025. The Company projects full year 2025 total operating expense of approximately $300.0 million and full year 2025 Adjusted EBITDA loss to be ($35.0) million, both are unchanged from previously issued guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept Biorobotics Corp. (PRCT) Q1 Earnings Cheat Sheet
- Procept BioRobotics price target lowered to $70 from $90 at Truist
- Procept BioRobotics announces WATER III randomized-controlled trial results
- Buy Rating on PROCEPT BioRobotics: Attractive Entry Point Amidst Growth Potential and Upcoming Clinical Catalysts
- Procept Biorobotics Earnings Call Highlights Growth and Challenges